The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
NeuroSense Therapeutics Ltd.(NASDAQ:NRSN)


NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin an...
Website: https://www.neurosense-tx.com
Founded: 2017
Full Time Employees: 11
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
NeuroSense Therapeutics . Op Cashflow Per Share ttm
NeuroSense Therapeutics . Free Cashflow Per Share ttm
NeuroSense Therapeutics . Cash Per Share ttm
NeuroSense Therapeutics . (GAAP) P/E ratio ttm
NeuroSense Therapeutics . P/B ratio ttm
No extra charts and metrics for this ticker.